
AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal
AstraZeneca (AZN.L) will take full control of Caelum Biosciences in a deal worth up to $500 million, the drugmaker said on Wednesday, sharpening its focus on rare-disease drugs following its ...